As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at therapeutics stocks, starting with Modern
In the most recent trading session, Moderna (MRNA) closed at $55.63, indicating a +2.89% shift from the previous trading day.
Moderna's stock recently hit a new 52-week high after receiving positive news surrounding one of its vaccines.
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Moderna (NASDAQ:MRNA) and its peers.
Wall Street Breakfast recap: stocks slide on oil surge, tech earnings, tariffs and Middle East tensions.
The days ahead pack several binary or near-binary catalysts for U.S. biotech and biopharma companies—decisions that could sharply reshape valuations overnight.
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Despite challenges in life sciences and European automotive sectors, Dassault Systemes SE (DASTF) reports robust revenue growth and strategic advancements in AI and cloud solutions.
View interactive chart, options flow, and AI analysis for MRNA on Zorveq Finance.
Open MRNA Chart & Analysis →